AFG
VKTX icon

Atomi Financial Group’s Viking Therapeutics VKTX Stock Holding History

Atomi Financial Group’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$278K Sell
7,126
-1,389
-16% -$44.9K 0.01% 1073
2026
Q1 		$277K Buy
+8,515
New +$274K 0.01% 999

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Atomi Financial Group's VKTX Position: Q2 2026 in Review

Atomi Financial Group reduced its Viking Therapeutics (VKTX) stake by 16% in Q2 2026, selling an estimated $44.9K and leaving 7,126 shares worth $278K. The position accounts for 0.01% of the portfolio, ranked #1073.

Atomi Financial Group first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Atomi Financial Group held 7,126 shares of Viking Therapeutics worth $278K as of Q2 2026.
  • Atomi Financial Group sold 1,389 Viking Therapeutics shares in Q2 2026, an estimated $44.9K.
  • Viking Therapeutics made up 0.01% of Atomi Financial Group's portfolio in Q2 2026, its #1073 holding.
  • Atomi Financial Group first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Atomi Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.